Maxigen Biotech Inc. (1783.TW)
TWD 41.1
(-1.2%)
TWD 41.1
(-1.2%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 85.18 Million TWD | 13.17% |
| 2022 | 75.27 Million TWD | -4.66% |
| 2021 | 78.95 Million TWD | -9.23% |
| 2020 | 86.98 Million TWD | -1.28% |
| 2019 | 88.11 Million TWD | 6.65% |
| 2018 | 82.61 Million TWD | -12.09% |
| 2017 | 93.97 Million TWD | 3.23% |
| 2016 | 91.04 Million TWD | -2.89% |
| 2015 | 93.74 Million TWD | 8.9% |
| 2014 | 86.08 Million TWD | 16.61% |
| 2013 | 73.82 Million TWD | 28.88% |
| 2012 | 57.28 Million TWD | 14.01% |
| 2011 | 50.24 Million TWD | 22.22% |
| 2010 | 41.1 Million TWD | 19.08% |
| 2009 | 34.52 Million TWD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 69.94 Million TWD | -10.46% |
| 2024 Q1 | 78.12 Million TWD | -8.29% |
| 2023 Q3 | 97.07 Million TWD | 12.32% |
| 2023 Q2 | 86.42 Million TWD | 14.39% |
| 2023 FY | 85.18 Million TWD | 13.17% |
| 2023 Q1 | 75.55 Million TWD | 0.37% |
| 2023 Q4 | 85.18 Million TWD | -12.24% |
| 2022 Q2 | 66.42 Million TWD | 7.15% |
| 2022 Q1 | 61.99 Million TWD | -21.48% |
| 2022 FY | 75.27 Million TWD | -4.66% |
| 2022 Q4 | 75.27 Million TWD | 2.56% |
| 2022 Q3 | 73.39 Million TWD | 10.48% |
| 2021 Q3 | 91.99 Million TWD | -6.02% |
| 2021 Q4 | 78.95 Million TWD | -14.17% |
| 2021 Q1 | 85 Million TWD | -2.28% |
| 2021 FY | 78.95 Million TWD | -9.23% |
| 2021 Q2 | 97.88 Million TWD | 15.16% |
| 2020 Q4 | 86.98 Million TWD | -0.18% |
| 2020 FY | 86.98 Million TWD | -1.28% |
| 2020 Q1 | 97.02 Million TWD | 10.11% |
| 2020 Q2 | 94.99 Million TWD | -2.09% |
| 2020 Q3 | 87.14 Million TWD | -8.27% |
| 2019 Q1 | 75.17 Million TWD | -9.01% |
| 2019 Q2 | 80.97 Million TWD | 7.71% |
| 2019 Q3 | 73.84 Million TWD | -8.8% |
| 2019 Q4 | 88.11 Million TWD | 19.32% |
| 2019 FY | 88.11 Million TWD | 6.65% |
| 2018 Q3 | 76.27 Million TWD | -5.06% |
| 2018 Q1 | 86.31 Million TWD | -8.16% |
| 2018 FY | 82.61 Million TWD | -12.09% |
| 2018 Q4 | 82.61 Million TWD | 8.32% |
| 2018 Q2 | 80.33 Million TWD | -6.92% |
| 2017 Q4 | 93.97 Million TWD | 1.18% |
| 2017 Q2 | 91.43 Million TWD | -9.42% |
| 2017 Q1 | 100.94 Million TWD | 10.88% |
| 2017 FY | 93.97 Million TWD | 3.23% |
| 2017 Q3 | 92.87 Million TWD | 1.57% |
| 2016 Q2 | 96.65 Million TWD | 0.83% |
| 2016 Q1 | 95.85 Million TWD | 2.25% |
| 2016 FY | 91.04 Million TWD | -2.89% |
| 2016 Q4 | 91.04 Million TWD | -3.78% |
| 2016 Q3 | 94.61 Million TWD | -2.11% |
| 2015 Q3 | 98.88 Million TWD | 3.79% |
| 2015 FY | 93.74 Million TWD | 8.9% |
| 2015 Q4 | 93.74 Million TWD | -5.2% |
| 2015 Q2 | 95.27 Million TWD | 9.81% |
| 2015 Q1 | 86.77 Million TWD | 0.8% |
| 2014 Q1 | 86.03 Million TWD | 16.55% |
| 2014 Q4 | 86.08 Million TWD | -0.43% |
| 2014 FY | 86.08 Million TWD | 16.61% |
| 2014 Q3 | 86.45 Million TWD | 7.43% |
| 2014 Q2 | 80.47 Million TWD | -6.47% |
| 2013 FY | 73.82 Million TWD | 28.88% |
| 2013 Q2 | 61.43 Million TWD | 0.0% |
| 2013 Q3 | 65.82 Million TWD | 7.14% |
| 2013 Q4 | 73.82 Million TWD | 12.16% |
| 2013 Q1 | - TWD | -100.0% |
| 2012 Q4 | 57.28 Million TWD | 0.0% |
| 2012 FY | 57.28 Million TWD | 14.01% |
| 2012 Q2 | 55.15 Million TWD | 0.0% |
| 2011 Q2 | 52.81 Million TWD | 0.0% |
| 2011 Q4 | 50.24 Million TWD | 0.0% |
| 2011 FY | 50.24 Million TWD | 22.22% |
| 2010 Q4 | 41.1 Million TWD | 0.0% |
| 2010 FY | 41.1 Million TWD | 19.08% |
| 2009 FY | 34.52 Million TWD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 705.32 Million TWD | 87.923% |
| SciVision Biotech Inc. | 87.25 Million TWD | 2.369% |
| Bionime Corporation | 491.25 Million TWD | 82.66% |
| Pegavision Corporation | 583.47 Million TWD | 85.401% |
| Visco Vision Inc. | 606.06 Million TWD | 85.945% |